A mucosal adjuvant for the inactivated poliovirus vaccine

Vaccine

Volumn 32, Issue 5, 2014, Pages 558-563

  Steil, Benjamin P ^a   Jorquera, Patricia ^a,c   Westdijk, Janny ^b   Bakker, Wilfried A M ^b   Johnston, Robert E ^a   Barro, Mario ^a,d  

^a Global Vaccines Inc   (United States)

^b Institute for Translational Vaccinology   (Netherlands)

^c UNIVERSITY OF GEORGIA   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Adjuvant; Alphavirus; Inactivated poliovirus vaccine; Mucosal immunity

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED POLIOVIRUS VACCINE GVI 3000; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; DOSE RESPONSE; DRUG COST; DRUG POTENCY; FEMALE; HEALTH CARE COST; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVERTANT; SEROTYPE; VIRAL CLEARANCE;

ADJUVANT; ALPHAVIRUS; INACTIVATED POLIOVIRUS VACCINE; MUCOSAL IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; POLIOVIRUS VACCINE, INACTIVATED; RATS;

EID: 84891659913     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.101     Document Type: Article

References (46)

1. Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology 2010, 172(December (11)):1213-1229.
2. Mdodo R.M., Wassilak S. Progress toward interruption of wild poliovirus transmission - worldwide, January 2011-March 2012. MMWR 2012, 61(19):353-357.
3. Racaniello V.R. One hundred years of poliovirus pathogenesis. Virology 2006, 344(1):9-16.
4. Okayasu H., Sutter R.W., Czerkinsky C., Ogra P.L. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 2011, 29(46):8205-8214.
5. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases 1991, 163(January (1)):1-6.
6. Ghendon Y., Robertson S.E. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bulletin of the World Health Organization 1994, 72(6):973-983.
7. Hird T., Grassly N. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathogens 2012, 8(4).
8. Duintjer Tebbens R.J., Pallansch M.A., Chumakov K.M., Halsey N.A., Hovi T., Minor P.D., et al. Expert review on poliovirus immunity and transmission. Risk Analysis 2012, 33(4):544-605.
9. Grassly N.C., Jafari H., Bahl S., Durrani S., Wenger J., Sutter R.W., et al. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. Journal of Infectious Diseases 2010, 201(10):1535-1543.
10. Grassly N.C., Jafari H., Bahl S., Sethi R., Deshpande J.M., Wolff C., et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. Journal of Infectious Diseases 2012, 205(10):1554-1561.
11. Alexander L., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004, 292(14):1696-1701.
12. Ogra P.L. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines. Annals of the New York Academy of Sciences 1995, 754(1):97-105.
13. Chumakov K., Ehrenfeld E., Plotkin S. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clinical Infectious Diseases 2008, 47(December (12)):1587-1592.
14. Alexander J.P., Ehresmann K., Seward J., Wax G., Harriman K., Fuller S., et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. Journal of Infectious Diseases 2009, 199(February (3)):391-397.
15. Kohler K.A., Banerjee K., Gary Hlady W., Andrus J.K., Sutter R.W. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bulletin of the World Health Organization 2002, 80:210-216.
16. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology 2005, 59(1):587-635.
17. Krugman S., Warren J., Eiger M.S., Berman P.H., Michaels R.M., Sabin A.B. Immunization with live attenuated poliovirus vaccine. American Journal of Diseases of Children 1961, 101(1):23-29.
18. Grassly N.C., Jafari H., Bahl S., Durrani S., Wenger J., Sutter R.W., et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. Journal of Infectious Diseases 2009, 200(September (5)):794-801.
19. Plotkin S.A., Vidor E. Poliovirus vaccine-inactivated. Vaccines 2008, 605-629, W.B. Saunders Company, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
20. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Review of Vaccines 2009, 8(7):899-905.
21. Duintjer Tebbens R.J., Pallansch M.A., Chumakov K.M., Halsey N.A., Hovi T., Minor P.D., et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Analysis 2012, 33(4):606-646.
22. Ivanov A.P., Dragunsky E.M., Chumakov K.M. 1,25-Dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. Journal of Infectious Diseases 2006, 193(February (4)):598-600.
23. Thompson J.M., Whitmore A.C., Konopka J.L., Collier M.L., Richmond E.M.B., Davis N.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(March (10)):3722-3727.
24. Thompson J.M., Nicholson M.G., Whitmore A.C., Zamora M., West A., Iwasaki A., et al. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. Journal of Immunology 2008, 181(July (1)):574-585.
25. Thompson J.M., Whitmore A.C., Staats H.F., Johnston R.E. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 2008, 26(33):4267-4275.
26. Tonkin D.R., Whitmore A., Johnston R.E., Barro M. Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine 2012, 30(30):4532-4542.
27. Westdijk J., Koedam P., Barro M., Steil B.P., Collin N., Vedvick T.S., et al. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 2013, 31(9):1298-1304.
28. Davis N.L., Caley I.J., Brown K.W., Betts M.R., Irlbeck D.M., McGrath K.M., et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. Journal of Virology 2000, 74(January (1)):371-378.
29. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239(2):389-401.
30. Davis N.L., Powell N., Greenwald G.F., Willis L.V., Johnson B.J.B., Smith J.F., et al. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 1991, 183(1):20-31.
31. van Steenis G., van Wezel A., Sekhuis V. Potency testing of killed polio vaccine in rats. Developments in Biological Standardization 1981, 47:119-128.
32. Tonkin D.R., Jorquera P., Todd T., Beard C.W., Johnston R.E., Barro M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010, 28(18):3238-3246.
33. Boom W.H., Liano D., Abbas A.K. Heterogeneity of helper/inducer T lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes. Journal of Experimental Medicine 1988, 167(April (4)):1350-1363.
34. Kim J.-H., Sohn H.-J., Lee J., Yang H.-J., Chwae Y.-J., Kim K., et al. Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri. Clinical and Vaccine Immunology 2013, 20(July (7)):1055-1060.
35. Kimoto T., Mizuno D., Takei T., Kunimi T., Ono S., Sakai S., et al. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses. Influenza and Other Respiratory Viruses 2013, May. 10.1111/irv.12124.
36. Cebra J.J., Logan A.C., Weinstein P.D. The preference for switching to expression of the IgA isotype of antibody exhibited by B lymphocytes in Peyer's patches is likely due to intrinsic properties of their microenvironment. Immunologic Research 1991, 10(3-4):393-395.
37. Plotkin S.A. Correlates of protection induced by vaccination. Clinical and Vaccine Immunology 2010, 17(July (7)):1055-1065.
38. Sangrujee N., Cáceres V.M., Cochi S.L. Cost analysis of post-polio certification immunization policies. Bulletin of the World Health Organization 2004, 82:9-15.
39. Thompson J.M., Whitmore A.C., Staats H.F., Johnston R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 2008, 26(39):4998-5003.
40. LoBue A.D., Thompson J.M., Lindesmith L., Johnston R.E., Baric R.S. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. Journal of Virology 2009, 83(April (7)):3212-3227.
41. Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P., et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. Journal of Infectious Diseases 2011, 203(April (7)):898-909.
42. MacLennan C., Dunn G., Huissoon A.P., Kumararatne D.S., Martin J., O'Leary P., et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004, 363(9420):1509-1513.
43. John T., Vashishtha V. Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status. Indian Journal of Medical Research 2013, 137:881-894.
44. Polio Global Eradication Initiative 2013, Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx [cited 10.01.13].
45. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Reviews of Infectious Diseases 1991, 13(5):926-939.
46. ® in rhesus macaques. Vaccine 2011, 29(5):931-940.